HHS Moves to Let Pharmacies Produce Unapproved Peptides — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration is proceeding with a plan to allow compounding pharmacies to produce certain peptides that have not been FDA-approved as safe or effective, per the Associated Press
- The peptides under consideration have gained popularity among followers of HHS Secretary Robert F. Kennedy Jr. and other wellness influencers
- Most available data on these peptides comes from animal studies, according to the AP
- China is proposing to add five biomedical technologies to its export-control list, per a Ministry of Commerce statement reported by Bloomberg Law
- The Chinese draft proposal includes two types of medical technology platforms aimed at treating diseases at a genetic level
- China's proposed restrictions explicitly exempt licensing agreements, partnerships, and contract research services involving the listed technologies
Why it matters: Compounding pharmacies could soon dispense unapproved peptides with efficacy evidence drawn largely from animal studies, shifting the safety judgment from the FDA to prescribers and patients; the parallel China move gives Beijing new leverage to selectively permit or restrict cross-border biotech licensing flows.
Ask SkimNews
